DK0877752T3 - Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler - Google Patents
Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekylerInfo
- Publication number
- DK0877752T3 DK0877752T3 DK97903068T DK97903068T DK0877752T3 DK 0877752 T3 DK0877752 T3 DK 0877752T3 DK 97903068 T DK97903068 T DK 97903068T DK 97903068 T DK97903068 T DK 97903068T DK 0877752 T3 DK0877752 T3 DK 0877752T3
- Authority
- DK
- Denmark
- Prior art keywords
- screening
- methods
- rna molecules
- effector peptides
- transdominant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58991196A | 1996-01-23 | 1996-01-23 | |
US08/589,109 US6365344B1 (en) | 1996-01-23 | 1996-01-23 | Methods for screening for transdominant effector peptides and RNA molecules |
PCT/US1997/001048 WO1997027213A1 (en) | 1996-01-23 | 1997-01-23 | Methods for screening for transdominant effector peptides and rna molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0877752T3 true DK0877752T3 (da) | 2003-09-15 |
Family
ID=27080449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97903068T DK0877752T3 (da) | 1996-01-23 | 1997-01-23 | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler |
Country Status (10)
Country | Link |
---|---|
US (5) | US6153380A (de) |
EP (2) | EP0877752B1 (de) |
JP (2) | JP2001509661A (de) |
AU (2) | AU1707497A (de) |
CA (1) | CA2244222A1 (de) |
DE (1) | DE69722176T2 (de) |
DK (1) | DK0877752T3 (de) |
ES (1) | ES2200150T3 (de) |
HK (1) | HK1016997A1 (de) |
WO (2) | WO1997027212A1 (de) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
DE69532127T2 (de) * | 1994-07-20 | 2004-08-26 | Genetics Institute, Inc., Cambridge | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
ATE407205T1 (de) | 1994-08-20 | 2008-09-15 | Gendaq Ltd | Verbesserung in bezug auf bindungsproteine bei der erkennung von dna |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US20050002902A1 (en) * | 1995-12-28 | 2005-01-06 | Liming Yu | Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections |
US6365344B1 (en) * | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
AU1707497A (en) * | 1996-01-23 | 1997-08-20 | Rigel Pharmaceuticals, Inc. | Methods for screening for transdominant intracellular effector peptides and rna molecules |
US5955275A (en) | 1997-02-14 | 1999-09-21 | Arcaris, Inc. | Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes |
US6060240A (en) * | 1996-12-13 | 2000-05-09 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
US6623922B1 (en) | 1997-02-14 | 2003-09-23 | Deltagen Proteomics | Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6969584B2 (en) | 1997-06-12 | 2005-11-29 | Rigel Pharmaceuticals, Inc. | Combinatorial enzymatic complexes |
DE19737562A1 (de) * | 1997-08-28 | 1999-05-06 | Otogene Biotechnologische Fors | Verfahren zur Identifizierung von Wechselwirkungen zwischen Proteinen bzw. Peptiden |
US6322973B1 (en) | 1997-11-07 | 2001-11-27 | Iconix Pharmaceuticals, Inc. | Surrogate genetics target characterization method |
US6197502B1 (en) * | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
US6846625B1 (en) | 1998-01-09 | 2005-01-25 | Cubist Pharmaceuticals, Inc. | Method for identifying validated target and assay combination for drug development |
US6475726B1 (en) | 1998-01-09 | 2002-11-05 | Cubist Pharmaceuticals, Inc. | Method for identifying validated target and assay combinations for drug development |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
DE19805334A1 (de) * | 1998-02-11 | 1999-08-12 | Otogene Biotechnologische Fors | Verfahren zur Entwicklung eines pharmazeutischen Wirkstoffes |
DE69933856D1 (de) | 1998-02-13 | 2006-12-14 | Koester Hubert | Verwendung von ribozymen zur bestimmung der funktion von genen |
AU746454B2 (en) | 1998-03-02 | 2002-05-02 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
EP1064369B1 (de) | 1998-03-17 | 2006-08-16 | Gendaq Limited | Nukleinsäurebindungsproteine |
WO1999053031A2 (en) * | 1998-04-08 | 1999-10-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for producing cell clone libraries |
CA2327830A1 (en) * | 1998-04-09 | 1999-10-21 | Iconix Pharmaceuticals Inc. | Methods for identifying genetic determinants associated with modulation of test compound activity |
US6461813B2 (en) * | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
US6897031B1 (en) * | 1998-04-17 | 2005-05-24 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in exocytosis |
US8334238B2 (en) * | 1998-04-17 | 2012-12-18 | Rigel, Inc. | Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries |
US20040002056A1 (en) * | 1998-05-12 | 2004-01-01 | Lorens James B. | Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors |
US7090976B2 (en) | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
US7001733B1 (en) * | 1998-05-12 | 2006-02-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement |
US7060433B1 (en) * | 1999-11-12 | 2006-06-13 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening using diphtheria toxin constructs |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
DE19829495A1 (de) * | 1998-07-02 | 2000-01-05 | Jacques Paysan | Reagenzien und deren Anwendung zur Untersuchung von Wechselwirkungen zwischen zellulären Molekülen und deren Lokalisation in Zellen |
EP1270746A1 (de) * | 1998-07-20 | 2003-01-02 | Inoxell A/S | Verfahren zur Erkennung von Liganden und Ziel-Biomolekülen |
WO2000005406A1 (en) * | 1998-07-20 | 2000-02-03 | M & E Biotech A/S | Novel methods for the identification of ligand and target biomolecules |
US6472151B1 (en) | 1998-08-19 | 2002-10-29 | Bristol-Myers Squibb Company | Method of screening for compounds that modulate the activity of a molecular target |
WO2000020859A1 (en) * | 1998-10-05 | 2000-04-13 | Duke University | METHOD AND APPARATUS FOR DETECTING BINDING INTERACTIONS $i(IN VIVO) |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
CA2362414A1 (en) | 1999-03-12 | 2000-09-14 | Gpc Biotech, Inc. | Methods and reagents for identifying synthetic genetic elements |
EP1165842A4 (de) * | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | Lentivirale vektorsysteme zur durchmusterung grosser mengen |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
DE69918260T2 (de) * | 1999-03-29 | 2005-07-14 | Michael Blind | Methoden zur Identifizierung und Validierung von funktionellen Zielen mittels Intrameren oder in vivo Selektion |
US6524797B1 (en) | 1999-05-10 | 2003-02-25 | Bernhard O. Palsson | Methods of identifying therapeutic compounds in a genetically defined setting |
JP2003500649A (ja) * | 1999-05-25 | 2003-01-07 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | 薬剤耐性の新規機構の同定 |
US6737240B1 (en) | 1999-05-25 | 2004-05-18 | Rigel Pharmaceuticals, Inc. | Methods of screening for a multi-drug resistance conferring peptide |
EP1055929A1 (de) * | 1999-05-26 | 2000-11-29 | Tibotec N.V. | Mittel und Verfahren für Medizinentdeckung und phenotypische Charakterisierung von Zellen |
AU2005209649B2 (en) * | 1999-05-31 | 2008-05-29 | Novozymes A/S | Screening method for peptides |
EP1187913A1 (de) * | 1999-05-31 | 2002-03-20 | Novozymes A/S | SCREENINGVERFAHREN FüR PEPTIDE |
AU2041901A (en) | 1999-11-09 | 2001-06-06 | Elitra Pharmaceuticals, Inc. | Genes essential for microbial proliferation and antisense thereto |
DK1228233T3 (da) * | 1999-11-10 | 2007-05-14 | Rigel Pharmaceuticals Inc | Fremgangsmåder og sammensætninger omfattende grönfluorescerende proteiner (GFP) fra Renilla |
CA2394850C (en) | 1999-12-06 | 2012-02-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
EP1242457B1 (de) * | 1999-12-28 | 2004-08-11 | Esbatech AG | Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen |
DE60126913T2 (de) | 2000-01-24 | 2007-06-28 | Gendaq Ltd. | Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne |
US6582899B1 (en) * | 2000-02-15 | 2003-06-24 | Deltagen Proteomics, Inc. | Methods for identifying agents that cause a lethal phenotype, and agents thereof |
US7566765B2 (en) * | 2000-03-06 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds containing a nine-membered carbon-nitrogen ring |
US7252952B2 (en) * | 2000-03-06 | 2007-08-07 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides for inhibiting protein—protein interaction |
AU2001247296A1 (en) * | 2000-03-06 | 2001-09-17 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides |
US7378248B2 (en) * | 2000-03-06 | 2008-05-27 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides for inhibiting protein-protein interaction |
WO2001075178A2 (en) * | 2000-04-04 | 2001-10-11 | Enanta Pharmaceuticals, Inc. | Methods for identifying peptide aptamers capable of altering a cell phenotype |
US6762031B2 (en) * | 2000-06-16 | 2004-07-13 | University Of Medicine And Dentistry Of New Jersey | Targeting viral vectors to specific cells |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
CA2416788A1 (en) * | 2000-07-31 | 2002-02-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
US20030148924A1 (en) * | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
DE10060959A1 (de) * | 2000-12-06 | 2002-06-20 | Aventis Res & Tech Gmbh & Co | Verfahren zur Isolierung und Identifizierung von Effektoren |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
CA2431308C (en) | 2000-12-07 | 2010-04-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US7700274B2 (en) | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US7820447B2 (en) | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
AU2002243645A1 (en) | 2001-01-22 | 2002-07-30 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
AU2002338446A1 (en) * | 2001-01-23 | 2002-11-05 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
US20020192675A1 (en) * | 2001-02-02 | 2002-12-19 | The University Of Rochester | Methods of identifying regulator molecules |
US20030175685A1 (en) * | 2001-02-22 | 2003-09-18 | Praecis Pharmaceuticals Inc. | Methods for identifying peptides which modulate a biological process |
IL142481A0 (en) * | 2001-04-05 | 2002-03-10 | Yissum Res Dev Co | A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof |
DE10119999A1 (de) * | 2001-04-23 | 2002-10-24 | Univ Heidelberg | Verfahren zur Identifizierung und Entwicklung von Substanzen oder Substanzgemischen die zelluläre Transport-, Prozessierungs- und Sekretionsprozesse beeinflussen |
US20050255464A1 (en) * | 2001-07-19 | 2005-11-17 | Hagen Frederick S | Methods for the identification of peptidyl compounds interacting with extracellular target molecules |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
BR0213097A (pt) * | 2001-10-05 | 2005-02-01 | Coley Pharm Gmbh | Agonistas e antagonistas sinalizadores do receptor 3 similar a toll |
WO2003038131A1 (en) * | 2001-11-01 | 2003-05-08 | Rensselaer Polytechnic Institute | Biocatalytic solgel microarrays |
WO2003040168A2 (en) * | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
WO2003072600A2 (en) | 2002-01-23 | 2003-09-04 | Gardner, Rebecca, Katherine | Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53 |
AU2003218350A1 (en) | 2002-03-21 | 2003-10-08 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US20030219723A1 (en) * | 2002-05-20 | 2003-11-27 | Lu Henry H. | Compositions and methods for screening and identifying anti-HCV agents |
EP1511843B1 (de) * | 2002-06-07 | 2006-03-29 | Sophion Bioscience A/S | Screening-verfahren |
US20100009856A1 (en) * | 2002-06-21 | 2010-01-14 | Sinogenomax Sompany LTD. | Randomized dna libraries and double-stranded rna libraries, use and method of production thereof |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
AU2003269851A1 (en) * | 2002-10-09 | 2004-05-04 | Novozymes A/S | A method for screening for an antimicrobial polypeptide |
WO2004041213A2 (en) * | 2002-11-04 | 2004-05-21 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
EP1563067A4 (de) * | 2002-11-04 | 2006-06-07 | Icogenex Corp | Verfahren zur identifizierung von agentien, die die struktur und die prozessierung eines membrangebundenen vorläuferproteins modulieren |
AU2004213452A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic GPCR targets in cancer |
EP1613206A2 (de) * | 2003-04-16 | 2006-01-11 | The University Of Mississippi | Immunostimulatorische mittel in botanika |
US20070135997A1 (en) * | 2003-04-23 | 2007-06-14 | Evangelos Hytopoulos | Methods for analysis of biological dataset profiles |
GB0313173D0 (en) * | 2003-06-07 | 2003-07-16 | Givaudan Sa | Improvements in or related to organic compounds |
NZ573737A (en) * | 2003-07-15 | 2011-06-30 | Univ Bar Ilan | Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator |
US7776584B2 (en) * | 2003-08-01 | 2010-08-17 | Genetix Limited | Animal cell colony picking apparatus and method |
EP1651161B1 (de) | 2003-08-07 | 2011-10-19 | HealOr Ltd. | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung |
US20050052687A1 (en) * | 2003-08-12 | 2005-03-10 | Murata Kikai Kabushiki Kaisha | Image processing device and communication terminal device |
CA2560751A1 (en) * | 2004-03-22 | 2005-10-06 | The Ohio State University Research Foundation | Methods for transfecting natural killer cells |
US7745196B1 (en) | 2004-03-25 | 2010-06-29 | Rigel Pharmaceuticals, Inc. | Methods and compositions for identifying peptide modulators of cell surface receptors |
WO2005115433A2 (en) * | 2004-05-24 | 2005-12-08 | Rigel Pharmaceuticals, Inc. | Methods for cyclizing synthetic polymers |
EP1751181B1 (de) | 2004-06-02 | 2012-08-15 | AdAlta Pty Ltd | Auf haifisch-ignar-domänen basierende bindungseinheiten |
WO2006039630A2 (en) * | 2004-10-02 | 2006-04-13 | Indiana University Research & Technology Corporation | Materials and methods for identifying compounds that modulate the cell cycle |
CA2603093A1 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
US20090220495A1 (en) | 2005-04-07 | 2009-09-03 | Abdallah Fanidi | Cancer Related Genes (PRLR) |
CA2604885A1 (en) | 2005-04-07 | 2006-10-19 | Guoying Yu | Cacna1e in cancer diagnosis, detection and treatment |
ZA200802546B (en) * | 2005-08-29 | 2009-10-28 | Healor Ltd | Methods and compositions for prvention and treatment of diabetic and aged skin |
JP4959710B2 (ja) * | 2005-11-01 | 2012-06-27 | レンセレアー ポリテクニック インスティテュート | 毒物学アッセイのための3次元細胞アレイチップおよびプラットフォーム |
US8242057B2 (en) * | 2006-06-26 | 2012-08-14 | Cleveland Biolabs, Inc. | Methods for identifying modulators of apoptosis |
CN102755649A (zh) * | 2007-07-30 | 2012-10-31 | 希尔洛有限公司 | 药物组合物及相关方法 |
ES2601827T3 (es) * | 2009-02-24 | 2017-02-16 | Arava Bio-Tech Ltd. | Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones |
US20100305002A1 (en) * | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
WO2010136485A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
EP2523677A2 (de) | 2010-01-11 | 2012-11-21 | Healor Ltd. | Verfahren zur behandlung von entzündungskrankheiten und -erkrankungen |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US20130164860A1 (en) | 2011-11-04 | 2013-06-27 | Technion Research & Development Foundation Ltd. | Affinity methods and compositions employing electronic control of ph |
GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
EP2812349B1 (de) | 2012-02-10 | 2021-09-01 | Cambridge Enterprise Limited | Verfahren zur charakterisierung von wechselwirkungsbereichen bei zielproteinen |
CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
GB2505237A (en) * | 2012-08-24 | 2014-02-26 | Stefan Grimm | Method of screening for therapeutic agents using cell lines including a reference cell line |
US10022372B2 (en) | 2013-04-19 | 2018-07-17 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
CA2986388C (en) | 2015-06-11 | 2024-02-27 | Genexine, Inc. | Modified interleukin-7 protein and uses thereof |
WO2016201409A1 (en) | 2015-06-12 | 2016-12-15 | Georgia State University Research Foundation | Compositions and methods for treating opioid tolerance |
KR102386735B1 (ko) | 2015-11-06 | 2022-04-14 | 주식회사 제넥신 | 변형된 인터루킨-7 융합 단백질의 제형 |
WO2017095191A1 (ko) | 2015-12-04 | 2017-06-08 | 주식회사 제넥신 | 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물 |
CN108697764A (zh) | 2015-12-04 | 2018-10-23 | 格纳西尼有限公司 | 含有免疫球蛋白fc融合白细胞介素-7融合蛋白的用于预防或治疗流感病毒感染的药物组合物 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4618578A (en) | 1984-07-17 | 1986-10-21 | Chiron Corporation | Expression of glycoprotein D of herpes simplex virus |
JP2584613B2 (ja) | 1985-03-30 | 1997-02-26 | バリベ、マール | 組換えdna技術によってdna、rna、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法 |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5266464A (en) | 1988-02-10 | 1993-11-30 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US4980281A (en) | 1988-02-10 | 1990-12-25 | Housey Gerard M | Method of screening for protein inhibitors and activators |
CH684094A5 (de) | 1988-03-21 | 1994-07-15 | Viagene Inc | Rekombinante Retroviren. |
DE68927933T2 (de) * | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
DE4002897A1 (de) | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken") |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
DE69132902D1 (de) | 1990-02-15 | 2002-02-21 | Univ North Carolina Chapel Hill | Methoden zur identifizierung heterofunktionaler fusionsproteine |
US5639595A (en) * | 1990-05-01 | 1997-06-17 | Isis Phamaceuticals, Inc. | Identification of novel drugs and reagents |
ATE143056T1 (de) | 1990-05-01 | 1996-10-15 | Isis Pharmaceuticals Inc | Identifikation von neuen medikamenten und reagenzien |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
JPH06500923A (ja) | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | パッケージング細胞 |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
DK0598029T3 (da) | 1991-08-07 | 2002-05-27 | W French Anderson | Retrovirale vektorer indeholdende interne ribosome indgangssteder |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5395750A (en) | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
JPH08500481A (ja) | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
EP0670905B1 (de) * | 1992-09-22 | 2003-07-23 | Biofocus Discovery Limited | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
AU6248994A (en) * | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
EP0688358A4 (de) | 1993-03-12 | 1997-10-01 | Univ Creighton | Verbesserte vektoren für die gentherapy |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
EP0788370A4 (de) * | 1993-07-09 | 1998-07-08 | Smithkline Beecham Corp | Zyklische, teilzufallige peptidbibliotheken |
WO1995004824A1 (en) * | 1993-08-05 | 1995-02-16 | Medvet Science Pty. Ltd. | Generation of dna libraries and retroviral vectors for same |
AU8091694A (en) | 1993-10-26 | 1995-05-22 | United Biomedical Inc. | Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics |
US6303574B1 (en) * | 1994-07-22 | 2001-10-16 | The University Of North Carolina At Chapel Hill | Scr SH3 binding peptides and methods of isolating and using same |
AU3204895A (en) * | 1995-02-01 | 1996-08-21 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
DK0832207T3 (da) * | 1995-06-02 | 2000-11-06 | M & E Biotech As | Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer |
US20010053523A1 (en) | 1995-06-02 | 2001-12-20 | M&E Biotech A/S. | Method for identification of biologically active peptides and nucleic acids |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
KR100793625B1 (ko) * | 1995-09-29 | 2008-01-11 | 인디아나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 바이러스-매개된 dna 전달을 향상시키는 방법에 의해생산된 생존성 세포 집단 및 이를 포함하는 세포 조성물 |
AU1707497A (en) * | 1996-01-23 | 1997-08-20 | Rigel Pharmaceuticals, Inc. | Methods for screening for transdominant intracellular effector peptides and rna molecules |
US5955275A (en) * | 1997-02-14 | 1999-09-21 | Arcaris, Inc. | Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes |
WO2000005406A1 (en) | 1998-07-20 | 2000-02-03 | M & E Biotech A/S | Novel methods for the identification of ligand and target biomolecules |
-
1997
- 1997-01-23 AU AU17074/97A patent/AU1707497A/en not_active Abandoned
- 1997-01-23 WO PCT/US1997/001019 patent/WO1997027212A1/en active Application Filing
- 1997-01-23 JP JP52698297A patent/JP2001509661A/ja not_active Ceased
- 1997-01-23 WO PCT/US1997/001048 patent/WO1997027213A1/en active IP Right Grant
- 1997-01-23 ES ES97903068T patent/ES2200150T3/es not_active Expired - Lifetime
- 1997-01-23 US US08/789,333 patent/US6153380A/en not_active Expired - Lifetime
- 1997-01-23 DK DK97903068T patent/DK0877752T3/da active
- 1997-01-23 CA CA002244222A patent/CA2244222A1/en not_active Abandoned
- 1997-01-23 AU AU17078/97A patent/AU725716C/en not_active Ceased
- 1997-01-23 JP JP9526969A patent/JP2000504220A/ja active Pending
- 1997-01-23 US US08/787,738 patent/US6455247B1/en not_active Expired - Lifetime
- 1997-01-23 DE DE69722176T patent/DE69722176T2/de not_active Expired - Lifetime
- 1997-01-23 EP EP97903068A patent/EP0877752B1/de not_active Expired - Lifetime
- 1997-01-23 EP EP02026164A patent/EP1295952A3/de not_active Withdrawn
-
1999
- 1999-05-17 HK HK99102175A patent/HK1016997A1/xx not_active IP Right Cessation
-
2001
- 2001-07-27 US US09/916,940 patent/US6737241B2/en not_active Expired - Fee Related
- 2001-07-30 US US09/918,601 patent/US20020146710A1/en not_active Abandoned
- 2001-07-31 US US09/919,635 patent/US20030104384A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU1707497A (en) | 1997-08-20 |
US20030104384A1 (en) | 2003-06-05 |
AU1707897A (en) | 1997-08-20 |
DE69722176T2 (de) | 2004-03-18 |
WO1997027213A1 (en) | 1997-07-31 |
US6737241B2 (en) | 2004-05-18 |
EP0877752A1 (de) | 1998-11-18 |
US20020127564A1 (en) | 2002-09-12 |
JP2000504220A (ja) | 2000-04-11 |
EP1295952A3 (de) | 2003-07-09 |
US20020146710A1 (en) | 2002-10-10 |
AU725716B2 (en) | 2000-10-19 |
AU725716C (en) | 2003-02-20 |
CA2244222A1 (en) | 1997-07-31 |
ES2200150T3 (es) | 2004-03-01 |
WO1997027212A1 (en) | 1997-07-31 |
EP1295952A2 (de) | 2003-03-26 |
DE69722176D1 (de) | 2003-06-26 |
US6455247B1 (en) | 2002-09-24 |
HK1016997A1 (en) | 1999-11-12 |
EP0877752B1 (de) | 2003-05-21 |
US6153380A (en) | 2000-11-28 |
JP2001509661A (ja) | 2001-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0877752T3 (da) | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler | |
DK0975708T3 (da) | Fremgangsmåder og materialer til nedbrydning af xanthan | |
DK0920631T3 (da) | Fremgangsmåde til identifikation af forbindelser, som indvirker på interaktioner mellem RNA og RNA-bindende proteiner | |
DK0811006T3 (da) | Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse | |
DK1084289T4 (da) | Fremgangsmåde og oplösningsmiddel til kemisk rensning | |
IS5158A (is) | Genaraðgreinir og aðferðir | |
NO972535D0 (no) | Metoder og apparater for DNA sekvenser og DNA identifikasjon | |
KR100309483B1 (ko) | 기체분석방법및장치 | |
DK0848911T3 (da) | Fremgangsmåde til isolering af en proteinsammensætning fra en muskelkilde og proteinsammensætning | |
DE69816789D1 (de) | Verfahren und system zur gestengesteuerten optionsauswahl | |
DK0954588T3 (da) | OB fusionsprotein-sammensætninger og fremgangsmåder | |
DK0909327T3 (da) | Erythromyciner og fremgangsmåder til deres fremstilling | |
DK0825946T3 (da) | Fremgangsmåde til lastning og behandling af hydrocarboner | |
AU3655899A (en) | Modified immunoglobulin molecules and methods for use thereof | |
DK1112174T3 (da) | Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf | |
DK0729951T3 (da) | Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder | |
DE69800431D1 (de) | Verbessertes Antennensystem und Verfahren hierfür | |
DE59805235D1 (de) | Testsystem und testverfahren | |
DK0863856T3 (da) | Komposteringssystem og fremgangsmåde | |
DK0911416T3 (da) | Fremgangsmåde til fremstilling af protein | |
DK0991666T3 (da) | Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf | |
DK0917879T3 (da) | Forbedret fremgangsmåde til stabilisering af proteiner | |
NO996090D0 (no) | Forbedret foskefor og fremgangsmåte for anvendelse av dette | |
NO971448D0 (no) | Anti-Fas rekombinante antistoffer og DNA derfor | |
DE69942195D1 (de) | Prozesssystem und -verfahren |